{
  "id": "5a760a4183b0d9ea66000016",
  "type": "summary",
  "question": "What is filgotinib?",
  "ideal_answer": "Filgotinib is an oral selective Janus kinase inhibitor. It has been tested in patients with rheumatoid arthritis and Chroni's disease, and has been shown to be safe and efficacious.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27988142",
    "http://www.ncbi.nlm.nih.gov/pubmed/27993828"
  ],
  "snippets": [
    {
      "text": "Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993828",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993828",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Over 24\u2005weeks, filgotinib as monotherapy was efficacious in treating the signs and symptoms of active RA, with a rapid onset of action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993828",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined the efficacy and safety of filgotinib for the treatment of moderate-to-severe Crohn's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the intention-to-treat population, 60 (47%) of 128 patients treated with filgotinib 200 mg achieved clinical remission at week 10 versus ten (23%) of 44 patients treated with placebo (difference 24 percentage points [95% CI 9-39], p=0\u00b70077). In a pooled analysis of all periods of filgotinib and placebo exposure over 20 weeks, serious treatment-emergent adverse effects were reported in 14 (9%) of 152 patients treated with filgotinib and three (4%) of 67 patients treated with placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Filgotinib induced clinical remission in significantly more patients with active Crohn's disease compared with placebo, and had an acceptable safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}